136
Participants
Start Date
February 28, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
NP001
Low dose of NP001
NP001
High dose of NP001
Placebo
normal saline
Columbia University, New York
SUNY Upstate Medical University, Syracuse, Syracuse
Duke University, Dept of Neurology, Durham
Carolinas Medical Center, Charlotte
The Emory Clinic, Atlanta
Mayo Clinic, Jacksonville, Jacksonville
Cleveland Clinic, Cleveland
University of Kansas Medical Center, Landon Center on Aging, Kansas City
Methodist Hospital Research Institute, Methodist Neurologic Institute, Houston
Mayo Clinic, Scottsdale, Scottsdale
UCLA, Los Angeles
California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center, San Francisco
Providence ALS Center, Portland
Providence Saint Peter Hospital, Centralia
UC, Irvine, Irvine
University of Kentucky, Department of Neurology, Lexington
Massachusetts General Hospital, Charlestown
Lead Sponsor
Neuraltus Pharmaceuticals, Inc.
INDUSTRY